



Ref.: NLL/CS/2024-325

1. National Stock Exchange of India Limited Listing Department, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai 400 051 Symbol: NECLIFE January 04, 2024

2. BSE Limited Corporate Relationship Department, P J Towers, Dalal Street, Mumbai 400 001 Scrip Code: 532649

Sub: Intimation – Update on Litigation(s) as required under Regulation 30 of the Securities and Exchange of Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

Dear Sir/ Madam,

This is with reference to point no. 5 of Annexure A of letter no. NLL/CS/2023-283 dated August 14, 2023, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations.

In terms of Regulation 30 of the LODR Regulations read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we are enclosing herewith necessary disclosures in prescribed format for details of updation of Litigation, as per Annexure 1.

The relevant extract of letter no. NLL/CS/2023-283 dated August 14, 2023, is attached as an Annexure 2.

This is for your information and record please.

Thanking you,

Yours faithfully, For Nectar Lifesciences Limited

(Neha Vaishnay) Company Secretary & Compliance Officer

Encl.: as above





Annexure 1

The Details of updation of Litigation of Nectar Lifesciences Limited ("Company")

Sr.	Regularly till the litigation is concluded or dispute is resolved:		
no.			
a)	The details of any change in the status and / or any development in relation to such proceedings;	-	
b)	In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings;	No <mark>t A</mark> pplicable	
c)	in the event of settlement of the proceedings, details of such settlement including - terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.	The appeal filed by the Company has been rejected. The Company has already deposited the full amount with interest i.e., 6.26 Crore. Therefore, there is no further financial implication towards the Company.	



Nectar Lifesciences Ltd.

Annexure 2

Sr no.	Brief details of litigation	Expected Financial Implication	Quantum of claims, if any	
5.	Name of Opposing Party: ABB Limited Forum where Pending: Supreme Court of India	ABB Limited had filed claims of Rs 6.26 Crore	As disclosed in financial implications	
	Brief Detail of the Case: The dispute pertains to installation and commissioning of Heating Ventilation Air Conditioner i.e., HVAC to be located at Unit VI and VII of the Company for the purpose of manufacturing of oral drugs. The dispute referred to arbitration and arbitration award passed against the Company. The said award was challenged by the Company before ADJ, Chandigarh, which were dismissed. The Company had filed an appeal, in High Court of Punjab and Haryana, during which the Company had deposited the award amount along with interest till the date of deposit i.e., Rs. 6.26 Crore. Thereafter, the Appeal was decided against the Company which was challenged before Supreme Court.	(inclusive of interest) whereas the Company had filed counter claim of Rs 13.22 Crore. Presently, the awarded amount along with interest stands paid by the Company.	column.	